at Investor's Business Daily (Jan 16, 2015)
United Therapeutics (UTHR) dives 11.8% after yesterday saying that the FDA has turned down the company's new drug application for treprostinil, an oral treatment for high blood pressure. The agency is uncertain whether another study would help change its mind, but said that if UTHR does decide on a further trial, it should consider a fixed dose design and more frequent dosing. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Investor's Business Daily (Jan 15, 2015)
at Benzinga.com (Jan 11, 2015)
at Benzinga.com (Jan 6, 2015)
at Benzinga.com (Jan 5, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs